PRKAG2 gene
protein kinase AMP-activated non-catalytic subunit gamma 2

Normal Function

The PRKAG2 gene provides instructions for making one part (the gamma-2 subunit) of a larger enzyme called AMP-activated protein kinase (AMPK). This enzyme helps sense and respond to energy demands within cells. It is active in many different tissues, including heart (cardiac) muscle and muscles used for movement (skeletal muscles). AMP-activated protein kinase is likely involved in the development of the heart before birth, although its role in this process is unknown.

AMP-activated protein kinase regulates chemical pathways involving the cell's main energy source, a molecule called adenosine triphosphate (ATP). The breakdown of ATP releases energy to drive many types of chemical reactions. AMP-activated protein kinase is activated during times of cellular stress (such as low oxygen levels or muscle exercise), when ATP is broken down rapidly to produce energy. If ATP levels become too low, the enzyme restores the balance of energy by limiting chemical reactions that require ATP and stimulating pathways that generate ATP.

Studies suggest that AMP-activated protein kinase may play a role in controlling the activity of other genes, although many of these genes have not been identified. The enzyme may also regulate the activity of certain ion channels in the heart. These channels, which transport positively charged atoms (ions) into and out of heart muscle cells, play critical roles in maintaining the heart's normal rhythm.

Health Conditions Related to Genetic Changes

Wolff-Parkinson-White syndrome

At least seven mutations that cause Wolff-Parkinson-White syndrome have been identified in the PRKAG2 gene. Some people with these mutations also have features of hypertrophic cardiomyopathy, a form of heart disease that enlarges and weakens the heart (cardiac) muscle. Researchers are uncertain how PRKAG2 mutations lead to the development of these heart conditions. Research suggests that these mutations alter the activity of AMP-activated protein kinase in the heart, disrupting the enzyme's ability to respond to changes in cellular energy demands. It is unclear, however, whether the genetic changes overactivate the enzyme or reduce its activity.

Studies indicate that changes in AMP-activated protein kinase activity allow a complex sugar called glycogen to build up abnormally within cardiac muscle cells. The accumulation of this substance enlarges these cells, which may lead to hypertrophic cardiomyopathy. Researchers continue to investigate whether an
abnormal buildup of glycogen in the heart is also responsible for the problems with
electrical signaling that are characteristic of Wolff-Parkinson-White syndrome.

Other studies have found that altered AMP-activated protein kinase activity is related
to changes in the regulation of certain ion channels in the heart. These changes may
help explain the increased risk of abnormal heart rhythms (arrhythmias) in people
with Wolff-Parkinson-White syndrome.

Familial atrial fibrillation

Familial hypertrophic cardiomyopathy

Other disorders

Several mutations in the PRKAG2 gene have been found in people with other
heart conditions. For example, a specific mutation in this gene is responsible for
a very severe form of heart disease called lethal congenital glycogen storage
disease of the heart. People with this mutation are born with extremely enlarged
hearts (cardiomegaly) and abnormal electrical signaling within the heart. These
abnormalities lead to respiratory distress and heart failure early in life. The mutation
responsible for this condition changes a single protein building block (amino acid)
in the gamma-2 subunit of AMP-activated protein kinase. Specifically, this mutation
replaces the amino acid arginine with the amino acid glutamine at position 531
(written as Arg531Gln or R531Q). Studies suggest that this severe disorder may be
related to the abnormal buildup of glycogen within cardiac muscle cells.

Other mutations in the PRKAG2 gene have been associated with disorders affecting
both cardiac and skeletal muscle. These mutations change single amino acids
in the gamma-2 subunit of AMP-activated protein kinase. Individuals with these
genetic changes typically experience muscle pain and stiffness, particularly following
exercise, in addition to hypertrophic cardiomyopathy and abnormal electrical
signaling within the heart. It is not known why the effects of some PRKAG2 mutations
appear to be confined to the heart, while other mutations cause signs and symptoms
affecting both cardiac and skeletal muscles.
**Chromosomal Location**

Cytogenetic Location: 7q36.1, which is the long (q) arm of chromosome 7 at position 36.1

Molecular Location: base pairs 151,556,114 to 151,877,115 on chromosome 7 (Homo sapiens Updated Annotation Release 109.20190905, GRCh38.p13) (NCBI)

Credit: Genome Decoration Page/NCBI

**Other Names for This Gene**
- AAKG
- AAKG2
- AAKG2_HUMAN
- AMP-activated protein kinase gamma2 subunit
- AMPK gamma2
- CMH6
- H91620p
- protein kinase, AMP-activated, gamma 2 non-catalytic subunit
- WPWS

**Additional Information & Resources**

**Scientific Articles on PubMed**
- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28PRKAG2%5BTIAB%5DV%29%29+OR+%28AMPK%5BTI%5DV%29+OR+%28AMP-activated+protein+kinase%5BTI%5DV%29+OR+%28AAKG%5BTIAB%5DV%29+OR+%28AM PK%5BTIAB%5DV%29+OR+%28AMP-activated+protein+kinase+gamma2+subunit%5BTIAB%5DV%29+OR+%28CMH6%5BTIAB%5DV%29+OR+%28H91620p%5BTIAB%5DV%29+OR+%28WPWS%5BTIAB%5DV%29+AND+%28Genes%5BMM%5DV%29+AND+english%5Bla nguage%5D+AND+human%5Bmh%5DV%29+AND+%22last+1800+days%22%5Bdp%5DV
Catalog of Genes and Diseases from OMIM

- GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL
  http://omim.org/entry/261740
- PROTEIN KINASE, AMP-ACTIVATED, NONCATALYTIC, GAMMA-2
  http://omim.org/entry/602743

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
  http://atlasgeneticsoncology.org/Genes/GC_PRKAG2.html
- ClinVar
- HGNC Gene Symbol Report
- Monarch Initiative
  https://monarchinitiative.org/gene/NCBIGene:51422
- NCBI Gene
- UniProt
  https://www.uniprot.org/uniprot/Q9UGJ0

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12015471

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11748095

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16443822

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16487706

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15766830

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14519435

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16836667


Reviewed: February 2007
Published: October 1, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services